SMMT · NASDAQ
Summit Therapeutics (SMMT) Stock Price & Fundamentals
Summit Therapeutics (SMMT) closed at $857.30 on Oct 9, 2026, down 0.93% from the previous close of $865.39.
Share price, past year
1Y +2.11%Monthly closing prices
| Date | Close |
|---|---|
| Oct 9, 2026 | $857.30 |
| Sep 30, 2026 | $861.24 |
| Aug 31, 2026 | $849.93 |
| Jul 31, 2026 | $850.37 |
| Jun 30, 2026 | $823.15 |
| May 29, 2026 | $846.74 |
| Apr 30, 2026 | $878.51 |
| Mar 31, 2026 | $906.48 |
| Feb 27, 2026 | $919.96 |
| Jan 30, 2026 | $901.36 |
| Dec 31, 2025 | $853.56 |
| Nov 28, 2025 | $833.81 |
| Oct 31, 2025 | $845.55 |
Key statistics
- Market cap
- $679.94B
- P/E (TTM)
- —
- EPS (TTM)
- −$1.11
- Revenue (TTM)
- —
- Net income (TTM)
- −$856.09M
- Shares outstanding
- 793.1M
- Dividend yield
- —
- 52-week range
- $789.32 – $950.56
Summit Therapeutics's market cap is $679.94B, based on a share price of $857.30 and 793.1M shares outstanding as of Jun 30, 2026.
Financials
Summit Therapeutics reported revenue of $0.00 for fiscal 2024.
Summit Therapeutics reported a net loss of $1.08B in fiscal 2025.
Annual revenue
| Fiscal year | Revenue | Growth | Net income | Net margin | EPS (diluted) | Free cash flow |
|---|---|---|---|---|---|---|
| FY2024ended Dec 31, 2024 | $0.00 | — | −$221.32M | — | −$0.31 | −$142.25M |
| FY2023ended Dec 31, 2023 | $0.00 | −100.0% | −$614.93M | — | −$0.99 | −$76.89M |
| FY2022ended Dec 31, 2022 | $705.00K | −61.0% | −$78.78M | −11,174.8% | −$0.41 | −$42.21M |
| FY2021ended Dec 31, 2021 | $1.81M | +110.4% | −$88.60M | −4,897.8% | −$0.67 | −$72.89M |
| FY2020ended Dec 31, 2020 | $860.00K | −98.5% | −$52.70M | −6,127.6% | −$0.76 | −$48.53M |
| FY2019ended Jan 31, 2019 | $57.09M | — | $10.87M | 19.0% | $0.63 | −$35.26M |
| Quarter | Revenue | Net income | EPS (diluted) |
|---|---|---|---|
| Q3 FY2024ended Sep 30, 2024 | $0.00 | −$56.25M | −$0.08 |
| Q4 FY2023ended Dec 31, 2023 | $0.00 | — | — |
| Q3 FY2023ended Sep 30, 2023 | $0.00 | — | — |
| Q2 FY2023ended Jun 30, 2023 | $0.00 | — | — |
| Q1 FY2023ended Mar 31, 2023 | $0.00 | — | — |
| Q4 FY2022ended Dec 31, 2022 | $0.00 | — | — |
| Q3 FY2022ended Sep 30, 2022 | $220.00K | — | — |
| Q2 FY2022ended Jun 30, 2022 | $235.00K | — | — |
Company profile
- Name
- Summit Therapeutics Inc.
- Ticker
- SMMT
- Exchange
- NASDAQ
- Industry (SEC SIC)
- Pharmaceutical Preparations
- Headquarters
- 601 Brickell Key Drive, Suite 1000, Miami, FL 33131
- Fiscal year ends
- December
- SEC CIK
- 0001599298
Recent SEC filings
- Sep 29, 2026
- Sep 15, 2026
- Sep 14, 2026
- Sep 3, 2026
- Aug 26, 2026
- Aug 5, 2026
- Jul 23, 2026
- Jul 23, 2026
Frequently asked questions
What is Summit Therapeutics's stock price?
Summit Therapeutics (SMMT) closed at $857.30 on Oct 9, 2026, down 0.93% from the previous close of $865.39.
What is Summit Therapeutics's market cap?
Summit Therapeutics's market cap is $679.94B, based on a share price of $857.30 and 793.1M shares outstanding as of Jun 30, 2026.
How much revenue does Summit Therapeutics make?
Summit Therapeutics reported revenue of $0.00 for fiscal 2024.
Does Summit Therapeutics pay a dividend?
Summit Therapeutics's recent filings report no dividends declared over the last four quarters.
Sources and methodology
Fundamentals come from Summit Therapeutics Inc.'s filings with the SEC (EDGAR XBRL company facts). Fourth-quarter figures that companies don't report separately are calculated as the fiscal year minus the first three quarters. Trailing twelve-month (TTM) figures sum the latest four quarters. Prices are generated sample data for development. Last updated Oct 9, 2026. Data sources and disclosures